Comparing XTL Biopharmaceuticals (XTLB) & The Competition

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare XTL Biopharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Valuation and Earnings

This table compares XTL Biopharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	-$6.97 million	-2.56
XTL Biopharmaceuticals Competitors	$702.30 million	$9.48 million	-18.96

XTL Biopharmaceuticals’ competitors have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

XTL Biopharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ competitors have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for XTL Biopharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	9873	15287	45632	1598	2.54

As a group, “Biotechnology” companies have a potential upside of 125.22%. Given XTL Biopharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares XTL Biopharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-12,323.33%	-195.91%	-30.60%

Insider & Institutional Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals competitors beat XTL Biopharmaceuticals on 7 of the 12 factors compared.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. is an Israeli clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company’s work is centered on treatments intended to regulate abnormal immune-system activity rather than broadly suppressing immune function. XTL’s principal development program has been hCDR1, also known as rigerimod, a synthetic peptide designed to modulate immune responses associated with systemic lupus erythematosus, or lupus. The candidate has been evaluated in clinical development for autoimmune indications, although its regulatory and commercial status may change as the company advances or revises its pipeline.